Replimune Group Inc. (REPL) stock
Price, quality score, analyst targets, a 30-day Kronos AI forecast and a Shariah screen for Replimune Group Inc., updated every trading day.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Price
$16.06
+23.07% today
Market cap
$1.2B
Overall quality
—
Kronos AI 30-day
−14.7%
1 of 8 simulated paths end higher
Replimune Group Inc. (REPL) is a Health Care company in Biotechnology: Biological Products (No Diagnostic Substances), worth $1.2B. It trades at $16.06, up 23.07% today. 7 analysts' average target of $19.86 implies +23.7% from today's price. Kronos AI's 30-day forecast is −14.7% (1 of 8 simulated paths end higher).
Open the full interactive analysis →Charts, technical signals, DCF fair value and ownership
Analyst price targets
| Average target | $19.86 |
| Low – high | $14.00 – $29.00 |
| Analysts | 7 |
| Upside to average | +23.7% |
Kronos AI 30-day forecast
| Expected close | $11.13 (−14.7%) |
| Likely range | −37.9% … −1.6% |
| As of | 2026-10-27 |
1 of 8 simulated paths end higher.
Quality scores
Not scored: the financial data for this listing is incomplete.
Shariah screen
| Business activity | Passes |
| Debt and cash (AAOIFI 30%) | Not checked for this listing |
Automated screen of business activity and AAOIFI's 30% debt and cash limits. The 5% impermissible-income test is not applied. Check with a scholar before deciding.
Similar companies in Biotechnology: Biological Products (No Diagnostic Substances)
For information only, not investment advice. Prices updated: 2026-10-29.